

HERAN Partners invests in Fluidic Sciences to support the expansion of its high-performance microfluidics platforms for biologics discovery and development.

Royston, UK —April 9, 2026.

HERAN Partners is pleased to announce a new investment in Fluidic Sciences Ltd, a UK-based life sciences tools company developing next-generation microfluidics technologies for antibody discovery, cell line development, cell engineering and biophysical analysis. The investment, made alongside BroadOak Capital Partners, will support the Company as it strengthens its commercial presence and advances its integrated “cell-to-molecule” workflow.

Fluidic Sciences brings together the technologies and know-how of SphereBio and Fluidic Analytics. Under the leadership of a seasoned team with deep operational experience in the life sciences tools sector, the Company has rapidly strengthened and consolidated two high-value complementary technology platforms. This will enable the Company to serve a growing customer base with a technically validated platform.

Fluidic Sciences develops high-throughput microfluidics systems for single-cell functional screening and in-solution biomolecular characterisation. Its flagship Cyto-Mine® and Cyto-Mine Chroma™ platforms integrate single-cell screening, sorting, and monoclonality verification in one instrument. The Fluidity One-M® platform measures biomolecular interactions in solution using Microfluidic Diffusional Sizing, enabling accurate affinity and binding-site analysis without immobilisation artefacts. Together, these technologies form a differentiated workflow designed to improve the speed, efficiency and quality of biologics research.

The Board of Directors of Fluidic Sciences includes Mark Gilligan (Executive Chairman), David Newble, and Andrew Lovatt. The management team is led by James Wilkinson (CEO), Andrew Lovatt (COO), and Richard Hammond (CTO).

Mercedes Tuin, Partner at HERAN Partners and new member of the Board of Directors, said: “Fluidic Sciences brings together two highly validated technologies that directly address the bottlenecks we consistently see in biologics R&D. We are particularly impressed by the maturity and deep connectivity of the team, which combines decades of experience in scaling life science tools businesses. We are excited to partner with them as they drive disciplined commercial expansion and build a category-defining platform in this space.”

Mark Gilligan, Chairman of the Board of Directors said: “Fluidic Sciences aims to give scientists unmatched insight at both the single-cell and molecular levels. Bringing together the Cytomine and Fluidity platforms allows us to deliver a powerful, integrated workflow that raises the bar for speed, data quality and ease of use in biologics discovery.”

He continues: “Over the past months, our team has worked with focus and care to stabilise, refine, and re-energise these platforms, ensuring that the value created over many years is not only preserved, but able to reach its full potential. We are delighted to be entering this next chapter with the support of partners who recognise both the strength of the underlying technologies and the commitment of the team behind them.”

Austin Duke, Managing Director at BroadOak Capital Partners adds: “We’ve followed this technology for years and believe Fluidic Sciences is uniquely positioned to lead the next wave of microfluidics-enabled discovery tools. The combination of technical depth, strong IP and proven customer demand makes this an exceptional opportunity.”

About Fluidic Sciences

Fluidic Sciences Ltd is a life sciences tools company based in Royston, UK, focused on high-performance microfluidics platforms for biologics discovery and development. Its technologies are used across antibody discovery, cell line development, cell engineering and advanced biophysical analysis.

For more information, visit: <https://fluidic.com/>.

About HERAN Partners

HERAN Partners is a specialist venture capital investor committed to creating transformative impact within the life sciences and healthcare industry. We are a Belgium-based investment fund driven by a dedicated team with strong scientific and entrepreneurial backgrounds. We provide venture & growth capital accompanied by a strong network, expertise and mentorship to start-ups and scale-ups with a solid technology platform and strong market potential.

Our investment philosophy centres around addressing emerging health challenges such as an ageing population, the surge in chronic diseases, and the associated increase in healthcare costs. We believe in harnessing the revolutionary potential of technology, science, and data to meet these challenges head-on. We focus on solutions that are solving an unmet need in the market. For more information visit: www.heranpartners.com.

About BroadOak Capital Partners

BroadOak Capital Partners is a life science focused, boutique financial institution that provides direct investment and investment banking services to companies in the research tools and consumables, diagnostics, and biopharma services sectors. BroadOak has led or participated in investments in more than 75 companies across multiple funds and investment vehicles and has advised on over 50 M&A transactions.

For more information visit www.broadoak.com.